NASDAQ Grants DARA BioSciences 180-Day Extension to Regain Compliance With Bid Price Requirement

NASDAQ Grants DARA BioSciences 180-Day Extension to Regain Compliance With Bid 
Price Requirement 
RALEIGH, NC  -- (Marketwired) -- 11/12/13 --  DARA BioSciences, Inc.
(NASDAQ: DARA), an oncology supportive care pharmaceutical company
dedicated to providing health care professionals a synergistic
portfolio of medicines to help cancer patients adhere to therapy and
manage side effects arising from cancer treatment, announced today
that the NASDAQ Listing Qualifications Staff has granted the
company's request for an additional 180-day period in which to regain
compliance with the minimum $1.00 bid price per share requirement. 
The NASDAQ Listing Qualifications Staff's determination to grant the
additional 180-day compliance period was based on the Company meeting
the continued listing requirement for market value of publicly held
shares and all other applicable requirements for initial listing on
the NASDAQ Capital Market, with the exception of the bid price
requirement, and the Company's written notice of its intention to
cure the deficiency during the additional 180-day compliance period
by effecting a reverse stock split, if necessary. 
About DARA BioSciences, Inc.  
DARA BioSciences Inc. is an oncology supportive care pharmaceutical
company dedicated to providing healthcare professionals a synergistic
portfolio of medicines to help cancer patients adhere to their
therapy and manage side effects arising from their cancer treatments. 
DARA holds exclusive U.S. marketing rights to Soltamox (tamoxifen
citrate) oral solution, the only liquid form of tamoxifen, used for
the treatment and prevention of breast cancer. Soltamox offers a
choice to patients who prefer or need a liquid form of tamoxifen.
Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and
effective relief of pain associated with oral mucositis caused by
chemotherapy and radiation treatment. DARA licensed the U.S. rights
to Soltamox from UK-based Rosemont Pharmaceuticals, Ltd., and
Gelclair from the Helsinn Group in Switzerland. Under an agreement
with Innocutis, DARA also markets Bionect (hyaluronic acid sodium
salt, 0.2%) a topical treatment for skin irritation and burns
associated with radiation therapy, in U.S. oncology/radiology
markets.  
DARA is focused on expanding its po
rtfolio of oncology supportive
care products in the United States, via in-licensing and/or
partnering of complementary late-stage and approved products. In
addition, the company wishes to identify a strategic partner for the
clinical development of KRN5500, currently in Phase 2 for the
treatment of chronic, treatment refractory, chemotherapy induced
peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a
Fast Track Drug, and DARA is seeking orphan status for the treatment
of CCIPN. For more information about the Company, visit
www.darabio.com. 
Safe Harbor Statement 
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the expectations
described in these forward-looking statements are set forth under the
caption "Risk Factors" in DARA's most recent Annual Report on Form
10-K, filed with the SEC on March 28, 2013 and DARA's other filings
with the SEC from time to time. Those factors include risks and
uncertainties relating to DARA's ability to timely commercialize and
generate revenues or profits from Bionect®, Soltamox®, Gelclair® or
other products given that DARA only recently hired its initial sales
force and DARA's lack of history as a revenue-generating company,
DARA's ability to achieve the desired results from the agreements
with Mission and Alamo, FDA and other regulatory risks relating to
DARA's ability to market Bionect, Soltamox, Gelclair or other
products in the United States or elsewhere, DARA's ability to
in-license and/or partner products, DARA's current cash position and
its need to raise additional capital in order to be able to continue
to fund its operations, the current regulatory environment in which
DARA sells its products, the market acceptance of those products,
dependence on partners, successful performance under collaborative
and other commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors identified
in the documents DARA has filed, or will file, with the Securities
and Exchange Commission ("SEC"). Copies of DARA's filings with the
SEC may be obtained from the SEC Internet site at http://www.sec.gov.
DARA expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with
regard thereto or any change in events, conditions, or circumstances
on which any such statements are based. DARA BioSciences and the DARA
logo are trademarks of DARA BioSciences, Inc. 
Media Contacts: 
David Connolly or Samantha Stenbeck
LaVoie Group
617-374-8800
dconnolly@lavoiegroup.com
sstenbeck@lavoiegroup.com 
Corporate Contact:
Jenene Thomas
DARA BioSciences
908-938-1475
jthomas@darabio.com  
 
 
Press spacebar to pause and continue. Press esc to stop.